Shots:Vividion (Bayer’s subsidiary) has acquired Tavros to strengthen its genomic capabilities via Tavros’ platform. The financial terms are undisclosed
The acquisition strengthens Vividion’s functional genomics expertise by adding proprietary genomic screening approaches to discover new targets & translate the known ones. Combining resources from both the companies will enable drug discovery in oncology…
